Skip to content

Efficacy and tolerability of a new reduced volume bowel preparation before colonoscopy. A multi-centre, randomised, observer-blind, comparative trial vs PEG + Ascorbate.

Efficacy and tolerability of a new reduced volume bowel preparation before colonoscopy. A multi-centre, randomised, observer-blind, comparative trial vs PEG + Ascorbate.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2010-019317-22-AT
Enrollment
Unknown
Registered
2010-05-17
Start date
2010-07-02
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medical conditions requiring the complete emptying of large intestin. MedDRA version: 12.1 Level: PT Classification code 10066943 Term: Bowel preparation

Interventions

Product Name: EASYGOL Product Code: PMF104 Pharmaceutical Form: Powder for oral solution CAS Number: 25322-68-3 Other descriptive name: MACROGOL 4000 Concentration unit: g gram(s) Concentration type:

Sponsors

PROMEFARM
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - patients aged between 18 - 85 years old - patients undergoing a complete colonoscopy Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - known or suspected gastrointestinal obstruction or perforation - toxic megacolon - major colonic resection - heart failure (Class III o IV), serious cardiovascular disease - severe liver failure - end-stage renal insufficiency - pregnant or at risk of becoming pregnant, lactating women - known or suspected hypersensitivity to the active principles or other ingredients, history of anaphylaxis to drugs or allergic reactions in general - phenylketonuria - glucose 6-phosphate dehydrogenase deficiency

Design outcomes

Primary

MeasureTime frame
Main Objective: To evaluate the efficacy in patients undergoing colonoscopy.;Secondary Objective: To evaluate mucosal visibility and patients safety, tolerability, compliance and acceptance.;Primary end point(s): Bowel cleansing as assessed by the validated Ottawa scale.

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026